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ight off the historic courtyard of the University
of Pennsylvania School of Veterinary Medicine
sits a large, sparsely decorated office, broken
into a maze of cubicles.
The nondescript nature of this space
belies the fact that for the past six years it has
served as the nerve center for an array of small-animal clinical
trials, stretching from this campus to the bench research facilities
of biomedical partners near and far.
Outside, a simple placard announces it as the Veterinary
Clinical Investigation Center (VCIC). Inside, a blackboard
mounted high on the back wall carries an inventory of some
two dozen current trials. A cursory review of partner institutions
past and present – the National Institutes of Health, Johns
Hopkins University, Penn State Hershey, as well as nearby Penn
Medicine and Children’s Hospital of Philadelphia – indicates
two things: the caliber and aspirations of these activities are
high, and most of the intended benefits serve both animal and
human patients.
Of the 28 veterinary schools in the United States, Penn Vet
is the first to create a research facility dedicated to the immense
promise of translational research.
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The Power of One
The words behind the Penn Vet mission – “Many Species, One
Medicine”– represent an understanding that veterinary practice
comprises diverse enterprises with a common purpose.
Much more recently, biomedical leaders have latched on
to the expression “one medicine” to describe the correlation
between many human and animal diseases, especially those found
in domesticated animals, primarily cats and dogs. A short list
of related conditions includes numerous cancers, infectious
diseases, allergies, autoimmune deficiencies, osteoarthritis and
chronic pain.
Joan Hendricks, V’79, GR’80, the Center’s founding
director and current Dean, was in many ways a perfect fit
for such an innovative concept. A passionate researcher who
specializes in the molecular basis of sleep regulation and
function, she holds a secondary appointment from Penn’s School
of Medicine and served as section chief for critical care at the
Matthew J. Ryan Veterinary Hospital.
“The best investment we can make as a School and a
community is to build our clinical research capabilities,” says
Dean Hendricks. “It helps us recruit and retain the best faculty,

commongood

Owner George Heath with 11-year-old Rocky.
Photo by Lisa Godfrey

raise the stature and importance of research
as it threads through Penn Vet’s work, and
connects this institution and its patients to
breakthrough diagnostics and therapeutics.”

A Delicate Balance
Without an integrated center such as VCIC
to oversee and support these clinical trials,
many of the activities underway would not
take place.
“I first realized how difficult it is to find
time for research when I began measuring
and managing chronic pain in dogs,”
says Dr. Dorothy Cimino Brown, the
Center’s current director. “The research
end of things always tends to suffer. That
needed to change.”
Brown shared her perspective with
Dean Hendricks, then Interim Chair of
Clinical Studies, unaware that the latter was
already in talks with Pfizer about building a

When Dr. John Lewis, V’97 went to the 2005
groundbreaking ceremony for the Vernon and Shirley
Hill Pavilion, he never expected that just being
there would help him break new ground in treating
patients with feline oral squamous cell carcinoma.
“It turned out a Penn Vet classmate is married to
Dr. Tom O’Brien, a Lankenau researcher working on
an experimental squamous cell drug,” says the assistant
professor of dentistry and oral surgery. “One thing
led to another and we began working together.”
With the support of the VCIC, the two men
embarked on a fruitful collaboration. Like many
biomedical researchers, O’Brien was looking for an
intermediary step between mouse models and human
clinical trials to provide important insights into his
drug’s potential adverse effects. Lewis sought better
options for the usually advanced and often inoperable
head and neck tumors he saw in his feline patients.
As with many joint projects, a creative combination
of funding underwrites their collaboration, from
governmental – the National Institutes of Health – to
very personal – a Penn Vet donor, Kathleen Jack, whose
cat Bud passed away from a squamous cell tumor.
Across medicine, finding more efficient ways to identify
promising drugs is a key goal. Of all the drugs developed,
only one in five make it from Phase I human clinical trials to
the market. Using small-animal studies to identify downsides
early on has major advantages: biomedical partners are able
to use human resources more sparingly and funders and
pharmaceutical companies can target financial resources
to those studies that continue to produce results.
Of course, not all human drug development can
leverage the advantages of veterinary trials. Those that
can Lewis likes to call “sparedels” – a new term he
credits to his Penn Vet colleague Dr. Lillian Duda, V’90,
an adjunct associate professor of radiation oncology.
“It stands for ‘spontaneous parallel reciprocal models’
with human disease,” explains Lewis. “I think this may soon
be accepted shorthand as more and more researchers on
the biomedical/human side of things realize translational
medicine is the future of bench-to-bedside research.
‘Sparedels’ will always provide you with more information
and more advances than experimental, induced cancers.”
In addition to the parallel advances he is
achieving with O’Brien, Lewis counts himself
fortunate to advance understanding about how
his feline patients tolerate medications.
“The VCIC is allowing us, as clinician educators,
to perform scholarly activity,” says Lewis. “You’re
usually pulled in four different directions at a time –
educating fourth-year students, rotating through service,
educating clients, teaching residents. Research is like
a quiet child – one who deserves more attention but
doesn’t always get it. The VCIC has helped change
this reality for good – and for the common good.”
www.vet.upenn.edu/bellwether 5

today – to gather robust data, keep protocols and support
reporting. Brown herself went back to school, earning a Masters
in Clinical Epidemiology from Penn to ensure greater in-house
expertise about clinical trial design, implementation and analysis.
The Center readily tapped into Penn Vet’s own technological
resources, from the latest in magnetic resonance imaging
to digital and intra-oral radiology, and found an essential
on-campus partner in the Investigational Drug Service at
the Hospital of the University of Pennsylvania. A “researchonly” pharmacy, it has the capacity to compound and dispense
investigational drugs.

Continuum of Support

VCIC staff member, Molly Love, CW’74, NU’81, GNU’84.
Photo by Lisa Godfrey

relationship with Penn Vet. The pharmaceutical giant embraced
the novel concept and the nascent Center set up shop managing
a small nucleus of Pfizer animal health studies.
These first trials provided useful primers in navigating
regulations and managing the logistical side of studies. “For
a canine osteosarcoma study – where our clinic normally
encounters just one or two cases a month – we had to find 100
subjects. How do you do that?” Brown found herself asking.
“We had to learn, practically overnight, how to creatively
recruit participants.”
Connections to community vets, especially alumni, were
tapped. Spots were aired on KYW News Radio. Over the
course of the year, one by one, the 100 dogs came through
the door.
Next followed the need for stronger human resources. The
first hire was a nurse/clinical trial coordinator – there are four
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The Center staff, comprised entirely of veterinarians, nurses
and vet technicians, quickly became expert at working with
clients who enroll their companion animals for VCIC studies.
At the heart of these relationships is a rigorous informed-consent
process for each meticulously designed and peer-reviewed study.
“It’s so important to express the scope, risk and potential
benefits accurately so owners and animals both feel protected,”
says Brown. “You especially cannot mislead owners of terminal
patients. They have to feel motivated to participate.”
One of VCIC’s current clients, George Heath, has embraced
the opportunity to enroll Rocky, his beloved 11-year-old
Rottweiler, in the osteosarcoma study.
“I found out about the study from my local veterinarian,”
says Heath, who lives in Chester County, Pennsylvania — an
hour-long drive from Ryan Veterinary Hospital in good traffic
but a relatively short trip when measured against his companion’s
welfare and happiness.
When Rocky arrived at Penn in March, a limp detected
the previous September and first treated with a common antiinflammatory drug, had turned into a debilitated gait that
indicated a great deal of pain. With radiation and chemotherapy
the only other options, the VCIC study, which focuses on pain
management, was a welcome alternative.
“To me, being part of this study means a lot because Rocky
is family. I’ve had him since he was a puppy,” Heath explains.
“This study offers better options and Rocky’s doing better. He’s
happy and he’s comfortable. If it helps other dogs and even
humans, so much the better.”
Each month, Heath and Rocky make the trip to the
Penn Vet campus for a physical and a data “dump” from the
microchip tag on Rocky’s collar, which constantly tracks his
vital signs and behavior.
Beyond these check-ups and information gathering, Heath
appreciates VCIC’s human touch. In this case, Molly Love,
CW’74, NU’81, GNU’84, is the nurse/clinical trial coordinator
who oversees Rocky’s case. “Molly’s always there by telephone
or e-mail if I need her,” he says. “She sends reports to my vet
right away. I couldn’t ask for more.

“In fact, I was just telling Molly my vet diagnosed another
Rottweiler with osteosarcoma. If that patient needs a reference, I
said, call me. I’ll let them know what a great program this is.”
Like Heath, many participants see VCIC as a welcome
lifeline, offering up-to-date information, access to novel
drugs and techniques, more affordable costs, and, above all,
the knowledge that they are helping future generations of
companion animals – and now people.
On September 23, 2009, the National Institutes of Health
treated the first human patient in its Phase 1 study of the pain

onlineupdate
To see how well Rocky is walking today
and to watch videos of other dogs
who have benefited from the VCIC
pain management research, please go
to www.vet.upenn.edu/bellwether.

Do you have
a dog with…

management treatment given to Rocky. The study, designed
for people with end-stage cancer, is highly restricted in its
participation criteria. Early results indicate that the patient
was free of debilitating daily pain. Truly, one — translational
— medicine.

Burgeoning Potential
From alternative medications to nanotechnology, VCIC never
stops seeking new ways to expand what can be accomplished
through translational research.
Today, the Center is made possible through gifts, grants and
clinical trials. Funding for new trials and advancing the Center’s
mission are being sought.
“The first two quarters of 2009 saw more studies initiated
than in all of 2008,” says Brown. “As investigators work with
us, they realize how much better it is to take advantage of our
infrastructure. Owners are happier to know they are advancing
science for the future. For us, it’s better all around.”
The Center’s team is happy, too, knowing that, among those
cubicles, they are indeed making history.
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. . . well-regulated Diabetes Mellitus
. . . bone cancer in need of pain management
. . . diagnosed with splenic hemangiosarcoma
. . . mast cell tumors not amenable to surgery
...O
 r a Doberman Pincher who needs a free cardiac evaluation
Penn’s Veterinary Clinical Investigation Center (VCIC) is looking for
you and your dog. Please call us to find out more about clinical trials.
Your dog may be qualified to participate in a study at the University
of Pennsylvania, Matthew J. Ryan Veterinary Hospital. For more
information call 215-573-0302 or email VCIC@vet.upenn.edu.
Please check our website for information
about other ongoing studies in the
VCIC at www.PennVCIC.org
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